ArticleThe New England journal of medicine2019
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Effect of sufentanil on the proliferation, apoptosis, and epithelial-mesenchymal transition of ovarian cancer cells by regulating the SMAD3/SNAIL signaling pathway.Journal of molecular histology · 2025Article
- Top-Down Proteomics of Human Saliva, Analyzed with Logistic Regression and Machine Learning Methods, Reveal Molecular Signatures of Ovarian Cancer.International journal of molecular sciences · 2023Article
- Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets.MedComm · 2023Review
- Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Article
- Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?Biomedicines · 2023Review
- APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Article
- Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.Diagnostics (Basel, Switzerland) · 2022Article
- SWAN pathway-network identification of common aneuploidy-based oncogenic drivers.Nucleic acids research · 2022Article
- Review
- Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer.Frontiers in oncology · 2022Article
- Article
- Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.Cancer research · 2021Article
- Breast Cancer Mortality among Women with aCancers · 2020Article
- Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors.Cell cycle (Georgetown, Tex.) · 2020Article
- A novel workflow for cancer blood biomarker identification.Annals of translational medicine · 2020Article
- Review
- Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020Review
- Article
- Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer.Frontiers in oncology · 2020Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.